Trend in approval of targeted biologics in the last two decades
View/ Open
Date
2024-04Publisher
Brac UniversityAuthor
Siddika, KhadizaMetadata
Show full item recordAbstract
Over the past two decades, the approval of targeted biologics has significantly transformed
therapeutic landscapes, particularly for chronic diseases like cancer. These therapies,
specifically target diseases' molecular pathways, offer enhanced efficacy and fewer side effects
than traditional chemotherapy. This review assesses the trends in regulatory approval by the
FDA, noting a surge in approvals for targeted biologics over the last two decades. The shift
towards targeted biologics promises more precise management of the complexities of cancer.
This review compiles the FDA's trends in approving targeted biologics for cancer from January
2000 to December 2022 based on product class, rate of approvals, biological target, and disease
site. Despite the advancements in targeted cancer therapies, there is a need to comprehensively
understand the evolving trends in FDA approvals during the twenty-first century. This study
investigates the approval patterns, identifies influencing factors, and provides insights that can
contribute to optimizing the development and processes of targeted biologics. This may serve
as a good insight for researchers in academia and industry to identify fields in which cancer
research and funding may be mostly directed.